Frontiers in immunology · 2025
miR-378a-5p targeting BRAF regulates CD4+T cells differentiation to Th1 under rEg.P29 induction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Tingting, Mu Hu, Wang Chuan, Qian Bingshuo, Zhu Mingxing
Аннотация
INTRODUCTION: Cystic echinococcosis (CE) is a globally distributed zoonotic disease caused by Echinococcus granulosus (Eg) that often presents with insidious onset and asymptomatic progression. Although several Eg-based recombinant vaccines have been developed for the prevention of CE, our previous study demonstrated that recombinant Eg.P29 (rEg.P29) is a potent immunogen that induces a robust Th1 immune response. Furthermore, microarray data from miRNA profiling of CD4+T cells isolated from mouse spleens showed that miR-378a-5p was significantly upregulated one week after immunization with rEg.P29.
METHODS: In this context, bioinformatics predictions and dual-luciferase reporter assays identified BRAF as a direct miR-378a-5p target, with downstream signaling involving the MAPK/ERK pathway.
RESULTS: Our research demonstrated that rEg.P29 immunization increased miR-378a-5p expression in naïve CD4+T cells, reduced BRAF, MEK1/2, and ERK1/2 expression, and promoted Th1 differentiation while inhibiting Th2 differentiation. Overexpression of miR-378a-5p in naïve CD4+T cells yielded similar results, whereas knockdown of miR-378a-5p had the opposite effect.
CONCLUSION: In summary, our findings reveal that under the induction of rEg.P29, miR-378a-5p targeted to BRAF regulation and initiated the differentiation of CD4+T cells in mouse spleen to Th1 direction, and MAPK/ERK pathway may be involved in this process, identifying miR-378a-5p as apotential biomarker and immunomodulatory target in CE.
METHODS: In this context, bioinformatics predictions and dual-luciferase reporter assays identified BRAF as a direct miR-378a-5p target, with downstream signaling involving the MAPK/ERK pathway.
RESULTS: Our research demonstrated that rEg.P29 immunization increased miR-378a-5p expression in naïve CD4+T cells, reduced BRAF, MEK1/2, and ERK1/2 expression, and promoted Th1 differentiation while inhibiting Th2 differentiation. Overexpression of miR-378a-5p in naïve CD4+T cells yielded similar results, whereas knockdown of miR-378a-5p had the opposite effect.
CONCLUSION: In summary, our findings reveal that under the induction of rEg.P29, miR-378a-5p targeted to BRAF regulation and initiated the differentiation of CD4+T cells in mouse spleen to Th1 direction, and MAPK/ERK pathway may be involved in this process, identifying miR-378a-5p as apotential biomarker and immunomodulatory target in CE.